Vibrant Pharma Secures Tens of Millions in Series A+ Financing Led by Sunshine Capital to Advance Next-Generation Immunotherapies into Global Clinical Development

Today, Apricot Forest Capital led the completion of a multi-million-dollar Series A+ financing round for Vibrant Therapeutics (Guangzhou) Co., Ltd. ("Vibrant"). Vibrant is an innovative company focused on the research and development of a new generation of intelligent macromolecular drugs. The funds will primarily be used to advance the company's core pipeline into global clinical trials, accelerate the development of First-in-Class (FIC) and Best-in-Class (BIC) drugs, and provide more effective treatment options for patients worldwide.

Vibrant was founded in 2019 by Dr. Larry Wang (Wang Luquan), the founder of Genscript. The company's core leadership team has an average of over 20 years of experience in large molecule drug research and development and has held key positions in well-known pharmaceutical and biotechnology companies such as Schering-Plough, Merck, and Genscript both in China and overseas. With deep expertise in the field of cancer immunotherapy, Vibrant is committed to developing next-generation intelligent large molecule drugs for solid tumors and other diseases. Vibrant’s independently developed intelligent molecular designThe platform combines computational prediction with experimental validation through a "dry-wet combination" R&D model, achieving a close integration of design and practical implementation.The efficient closed-loop verification accelerates the screening and optimization of drug candidate molecules, enhancing design precision to address unmet clinical needs. The funds from this round will also be used to expand the talent team and further advance self-developed projects.

VibrantDr. Luquan Wang, CEO, stated: "There are still significant unmet needs in the treatment of solid tumors and other areas. New-generation immunotherapies offer new possibilities to break through current treatment bottlenecks. Thanks to the support of both new and existing investors, we will accelerate the clinical research of our core pipelines, striving to bring more effective and safer revolutionary therapies to patients worldwide. Meanwhile, we also welcome more like-minded R&D talents to join Vibrant Therapeutics, to jointly advance the progress of treatments for solid tumors and other diseases."

Dr. Qiang Jing, Managing Partner of Apricot CapitalSaid: "TCEIn the field of diseases such as cancer, it is gradually showing great clinical value, while molecular design and development still have many issues that need to be resolved and optimized. Vibrant Therapeutics possesses strong technical capabilities and a clear strategic layout. Apricot Capital values the professional background and execution ability of their team, and is willing to work together with Vibrant Therapeutics to build a global leading enterprise in the next generation of cancer immunotherapy."

Vibrant is an innovative company dedicated to the research and development of a new generation of intelligent macromolecular drugs, founded by a team of experienced drug development experts.2019Founded in [Year]. The company focuses on the field of tumor immunotherapy, committed to developing first-in-class and best-in-class innovative drugs with global competitiveness, providing patients with better treatment options.